FINWIRES · TerminalLIVE
FINWIRES

Lupin Gets US FDA's Nod for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablet

By

Indian pharmaceutical company Lupin (NSE:LUPIN, BOM:500257) has received approval from the U.S. Food and Drug Administration for its Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets in the strengths of 1.479 grams, 0.225 grams, and 0.188 grams.

The tablets are bioequivalent to Azurity Pharmaceuticals' reference listed drug, Sutab Tablets, which are used to cleanse the colon as a preparation for colonoscopy in adults.

Lupin said it is eligible for 180-day generic drug exclusivity as it was the first to file for the product, which will be manufactured at Lupin's Nagpur facility in India.

IQVIA data estimates annual sales of $132.8 million for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets in the U.S. in the 12 months ended March.

Related Articles

Asia

Genrix Grants CQ Pharmaceutical Distribution Rights for Myeloma Drug in China, Hong Kong, Macau, Taiwan

Chongqing Genrix Biopharmaceutical (SHA:688443) granted C.Q. Pharmaceutical (SHE:000950) subsidiary Yaoyou Pharmaceutical exclusive development and distribution rights for the GR1803 drug across China and Hong Kong, Macau, and Taiwan.The agreement covers development such as clinical trials, research, and manufacturing, as well as sales, the filing said.The GR1803 velitumimumab drug is indicated for multiple myeloma, a rare form of blood cancer.Yaoyou will pay Genrix up to 600 million yuan in initial payment, listing milestone, and technology transfer milestone payments.Genrix will also be eligible to receive sales royalties of up to a minimum percentage of two digits.

SHA:688443SHE:000950
Asia

Xuan Wu Cloud's CFO Steps Down

Xuan Wu Cloud Technology's (HKG:2392) Chief Financial Officer Ge Ping resigned to devote more time to personal affairs effective May 31, according to a Friday Hong Kong bourse filing.

HKG:2392
Asia

Update: Xi'an Eswin Materials Technology to Invest Up to 40 Million Yuan in Glassmaker's Funding Round

Xi'an Eswin Materials Technology (SHA:688783) will invest up to 40 million yuan in a pre-A+ funding round for Zhuhai Yiyuan Technology, according to a Friday filing with the Shanghai bourse.Zhuhai Yiyuan Technology seeks to raise between 100 million yuan and 200 million yuan in a funding round.The glass manufacturer plans to use the proceeds for capacity expansion, equipment procurement, and technology upgrades.

SHA:688783